Jersey Couple Gives $1M to Speed Medical Breakthroughs

For most of her life, Carly Silvester woke up at 1am struggling to breathe, her severe asthma controlling every choice she made.

Diagnosed at seven, the Jersey resident lived with one of the most serious forms of asthma. Being near horses or eating certain foods could trigger attacks that left her gasping for air.

Her younger years were marked by constant hospital visits, steroid treatments, and flare-ups that dictated what she could and couldn't do. Then she was referred to specialists at the University of Southampton.

Professor Hans Michael Haitchi started Carly on Mepolizumab, a drug that targets the molecule responsible for triggering inflammation in the airways of severe asthma patients. The treatment blocks the overproduction of white blood cells that cause chronic breathing problems.

The change was profound. "After a few months, my life began to change," Carly recalled. "I stopped waking in the night, gasping for air."

Today, she says her asthma no longer dictates her life. "There is not really anything I cannot do now as a result of my asthma," she said.

Southampton researchers played a key role in developing Mepolizumab from early safety trials through real-world patient studies. Approved in 2017, it has since become a widely used treatment for severe asthma that doesn't respond to conventional therapies.

Now Jersey couple James and Mindy Vernon want to help create more breakthroughs like the one that changed Carly's life. They've donated $1 million toward Southampton's proposed Institute for Medical Innovation, a $100 million project bringing together doctors, scientists, engineers, and data specialists.

The Ripple Effect

The Vernons' gift will fund the Digital Collaboration Hub, a facility housing high-performance computing systems and AI tools to speed up scientific discovery. More than 7,000 Jersey patients were referred to Southampton in 2024 alone, making this connection deeply personal for the island community.

The institute will focus on five major disease areas: cancer, dementia, sight loss, infection, and respiratory conditions like asthma. "This new centre represents a remarkable chance to go further than ever before and create better outcomes for patients," James Vernon said.

Professor Paul Elkington, the institute's director, says the goal is helping life-changing treatments reach patients sooner. "The result will be smarter drugs, innovative devices, and kinder treatments reaching patients in years, not decades."

The Institute for Medical Innovation expects to be fully operational by 2030, creating a future where more patients like Carly can finally breathe easy.